AIRFLOW-2 two-year data confirm sustained reduction of severe COPD exacerbation risk vs. a control group. MINNEAPOLIS, Nov. 23, 2020 /PRNewswire/ — Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, announced today publication of two-year follow-up data from its randomized, sham-controlled, double-blinded trial (AIRFLOW-2) that confirms long-term safety and durable effect of Targeted Lung Denervation […]
Inspire Medical Systems CEO Tim Herbert has joined Nuvaira Board of Directors MINNEAPOLIS, June 8, 2020 – Nuvaira, a developer of novel therapeutic strategies to treat obstructive lung diseases, has announced that its Nuvaira® Lung Denervation System has been designated as a Breakthrough Device by the U.S. Food and Drug Administration (FDA). This program creates […]
A first for Temple University Hospital and U.S. Patients MINNEAPOLIS, June 10, 2019 – Nuvaira, developer of novel therapeutic strategies to treat obstructive lung diseases, announced the first treatments in the AIRFLOW-3 pivotal trial, the first interventional COPD trial to target reduction in COPD exacerbations as a primary endpoint. Two U.S. patients were successfully treated […]
Novel program provides reimbursement for TLD therapy in France MINNEAPOLIS, April 28, 2019 – Nuvaira, developer of novel therapeutic strategies to treat obstructive lung diseases, has received acceptance from the Haute Autorité de Santé (HAS, the French health technology assessment agency) into its Forfait Innovation program. The program is designed to fast-track novel medical devices […]
6500 Wedgwood Road North, Ste. 100
Minneapolis, MN 55311
Nuvaira Lung Denervation System is an investigational device in the United States and has CE mark regulatory approval in the European Economic Area (EEA).
Ce dispositif médical est un produit de santé réglementé qui porte, au titre de cette réglementation, le marquage CE. En France, le système de Dénervation Ciblée des Poumons dNerva ne fait pas l’objet d‘un dépôt de dossier de remboursement par les organismes d’assurances maladie.